Patients with relapsed or refractory diffuse large B-cell lymphoma undergoing autologous bone marrow transplantation benefited from consolidative involved-field radiotherapy (IFRT). All patients who underwent consolidative IFRT had improved locoregional control. Additionally, patients with enlarged lymphadenopathy had an improved locoregional control, disease-free survival, and overall survival at the 2-year evaluation. Introduction: We evaluated the role of consolidative radiotherapy (RT) for patients undergoing high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Materials and Methods: We reviewed the medical records of 72 consecutive patients who had undergone ASCT for relapsed or refractory DLBCL at our institution from 2006 to 2014. Pretransplant conditioning consisted of HDC and total body irradiation. Of the 72 patients, 13 received post-transplant consolidative RT at the discretion of the consulted radiation oncologist. Results: Consolidative RT was associated with significantly improved 2-year locoregional control (LRC) (92% vs. 68%; P ¼ .04). However, no difference was seen in either the 2-year progression-free survival (PFS) (69% vs. 54%; P ¼ .25) or overall survival (OS) (85% vs. 59%; P ¼ .44). Analysis of the subgroup of 19 patients with persistent residual masses ! 2 cm on post-transplant imaging demonstrated a significant improvement in LRC (100% vs. 36%; P < .01), PFS (88% vs. 27%; P ¼ .01), and OS (100% vs. 45%; P ¼ .02) with consolidative RT. Conclusion: The use of consolidative RT after HDC and ASCT for relapsed or refractory DLBCL appears to significantly improve LRC. For patients with masses ! 2 cm after ASCT, improved 2-year PFS and OS were seen. Prospective trials are needed to further identify the patients who would derive the most benefit from consolidative RT in the ASCT setting.
Introduction
Diffuse large B-cell lymphoma (DLBCL) accounts for 40% of all newly diagnosed cases of non-Hodgkin lymphoma. 1 Conventional combination chemotherapy can induce a complete response (CR) in w60% of patients. However, some patients will present with primary refractory disease and, among patients who achieve an initial CR, a significant proportion will develop a relapse. After the conclusion of the Parma Study Group trial, high-dose chemotherapy (HDC) combined with autologous stem cell transplantation (ASCT) became the standard salvage approach for relapsed or refractory DLBCL. 2 However, only 40% to 50% of patients with chemotherapy-sensitive relapse and 30% of those with primary refractory disease will achieve long-term progression-free survival (PFS) after ASCT. The patterns of failure in the patients with recurrence despite HDC-ASCT have largely been within the sites of previous disease involvement. 3, 4 This has generated increased interest in the use of consolidative involved-field radiotherapy (IFRT) with the hope of improving post-ASCT outcomes. 2, [4] [5] [6] To the best of our knowledge, no high-quality prospective randomized trials have directly addressed the utility of consolidative IFRT. Thus, the benefit of RT in the transplant setting has often been extrapolated from single institutional retrospective series. A review of these data, however, demonstrated conflicting information regarding the use of consolidative IFRT and its role for patients undergoing ASCT for relapsed or refractory disease.
We examined the clinical efficacy of consolidative IFRT in a group of patients who had undergone ASCT at our institution for relapsed or refractory DLBCL. We report the results of a retrospective analysis of 72 patients who had undergone HDC and ASCT in accordance with a single institutional protocol at the University of Minnesota (UMN).
Materials and Methods

Patients
We reviewed the medical records of 72 consecutive patients who had undergone HDC and ASCT for relapsed or refractory DLBCL (43 males and 29 females) at the UMN according to a single institutional protocol from 2006 to 2014. This institutional protocol provided stringent inclusion criteria for patients to undergo ASCT for relapsed or refractory DLBCL, including age < 75 years, Karnofsky performance score > 80%, and no serious organ Consolidative RT After ASCT for Relapsed or Refractory DLBCL dysfunction. Patients with primary refractory disease could be considered for ASCT if they had high-risk features, including stage IV disease at diagnosis, lactate dehydrogenase levels > 2 times normal, or > 2 extranodal sites of disease. Of the 72 patients, 9 (12.5%) had primary refractory disease (with high-risk features) and 63 (87.5%) had undergone ASCT after their first relapse. Many patients were in their second or later CR (n ¼ 44). To be eligible for ASCT, the patients had to have responded to pretransplant conditioning to the extent that they were in remission or had responding disease as determined by the pre-ASCT computed tomography (CT) and positron emission tomography (PET) scans. All patient data were prospectively collected in the UMN bone marrow transplantation database. These data were supplemented with details regarding radiation therapy obtained from the patients' medical records. The institutional review board at UMN approved the present study.
Transplant Protocol
Transplant conditioning consisted of cyclophosphamide 60 mg/ kg administered on days À7 and À6, followed by 1320 cGy total body irradiation (TBI) delivered on days À4 through À1 in 8 twicedaily fractions of 165 cGy using a parallel opposed technique. 7, 8 We reinfused previously collected peripheral blood stem cells on day 0. An alternative chemotherapy-only conditioning regimen using BEAM (carmustine, etoposide, cytarabine, melphalan) was given to 8 patients who had received previous RT with a cumulative organ dose deemed too high to safely deliver TBI.
Follow-up Protocol
All patients underwent regular repeat staging by CT at day 28 and 3, 6, 12, and 24 months after ASCT and by PET at day 100. The Deauville criteria were used to determine the treatment response. A Deauville score < 4 was considered to indicate a CR. We reviewed the day 28 and pre-ASCT CT scans to determine the size of the residual lymph nodes. Bone marrow biopsies were obtained at the follow-up CT scans for patients with previous bone marrow involvement. Patients were considered to have developed a relapse if new or enlarged lesions were identified on regular CT scans. Toxicities or adverse events were recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events. Each category of adverse event is reported, rather than the highest grade adverse event experienced per patient.
Consolidative RT
Consolidative IFRT was recommended if a patient had persistent nodal masses ! 2 cm on the day 28 CT scan, sites clinically suspicious for residual disease, or if they were believed to have a high risk of relapse. The radiation fields were selected on a case-by-case basis, with the all patients undergoing CT planning, with the suspicious areas contoured, followed by 3-dimenionsal conformal IFRT, which included adjacent nodal regions (n ¼ 12) or the involved node alone (n ¼ 1). Of the 72 patients, 19 had residual nodal disease ! 2 cm on post-ASCT imaging; however, only 8 of these patients underwent consolidative IFRT. The reasons for omission of consolidative IFRT included previous radiation (n ¼ 1), comorbidities (n ¼ 4), progressive disease at post-ASCT imaging (n ¼ 3), and unknown reasons (n ¼ 3). An additional 5 patients with a residual tumor volume < 2 cm underwent consolidative IFRT. Therefore, 13 patients had undergone consolidative IFRT after ASCT. The median IFRT dose was 3060 cGy (range, 3060-3600 cGy), and IFRT was completed a median of 110 days (range, 62-132 days) after ASCT.
Statistical Analysis
We defined the date of relapse for a patient as the first day that findings were observed on either clinical examination or imaging. The duration of locoregional control (LRC), PFS, and overall survival (OS) was measured from the date of ASCT. For the purposes of the present study, LRC was defined as disease control within the areas of involvement before ASCT. The distribution of LRC, PFS, and OS was estimated using the Kaplan-Meier method. The effect of consolidative IFRT on LRC, PFS, and OS was determined using the log-rank Cox proportional hazards model. P values < .05 were considered statistically significant.
Results
The patient characteristics are listed in Table 1 . No significant differences were present between the consolidative IFRT group and the observation group in terms of sex, age at ASCT, previous consolidative IFRT, disease status (primary refractory or relapsed), anatomic sites of involvement, stage at relapse, conditioning regimen, or follow-up duration. Fewer patients with B symptoms received consolidative IFRT (47% vs. 8%; P < .01). As expected by the treatment protocol, patients who had undergone consolidative IFRT tended to have a greater incidence of residual nodal disease ! 2 cm found on post-ASCT imaging (47% vs. 19%; P < .01) and on pre-ASCT imaging (62% vs. 19%; P < .01). Fourteen patients (19%) had undergone previous consolidative RT; however, these patients were equally likely to have received consolidative IFRT in the post-ASCT setting as the group of patients who had not received previous RT (15% vs. 20%; P ¼ .68). The median follow-up period for the entire group was 747 days (range, 33-3305 days).
Of the 72 patients, 31 developed a relapse (43%) and 16 died (22%) within 2 years of ASCT. Of the 31 relapses, 20 (65%) occurred at previous sites of disease, representing locoregional failure. The 2-year LRC, PFS, and OS rates were 72%, 57%, and 78%, respectively. As stated, 13 patients (18%) had undergone consolidative IFRT to 17 sites. The sites of consolidative IFRT included the abdomen (n ¼ 8), pelvis (n ¼ 3), head and neck (n ¼ 2), mediastinum (n ¼ 2), and axilla (n ¼ 2). An association between consolidative IFRT and significantly improved 2-year LRC (92% vs. 68%; P ¼ .04) was observed; however, no difference was seen in the 2-year PFS (69% vs. 54%; P ¼ .25) or 2-year OS (85% vs. 59%; P ¼ .44) rates. KaplanMeier plots of the entire cohort are depicted in Figure 1 .
The results of the univariate analysis of the factors affecting the 2-year LRC, PFS, and OS are listed in Table 2 . The 2-year OS was worse for patients with B symptoms (66% vs. 86%; P ¼ .05), and the 2-year PFS was worse for female patients (67% vs. 41%; P ¼ .04); however, other factors were not predictive of PFS or OS.
Because of our particular interest in the utility of consolidative IFRT, we performed a subgroup analysis of the patients who had and had not undergone consolidative IFRT after ASCT (Table 3) . No statistically significant improvement was seen with consolidative IFRT when stratified by patient sex, age at ASCT, date of ASCT, presence of B symptoms, previous RT, disease state (relapsed vs. primary refractory), conditioning regimen, or pre-ASCT Deauville score.
Of the 72 patients, 19 had enlarged nodal disease ! 2 cm noted on the day 28 imaging studies. Of these 19 patients, 15 (79%) had a Deauville score of 4 on the pre-ASCT PET imaging studies. The patients who had received consolidative IFRT had better 2-year LRC, PFS, and OS (P < .01, P < .01, and P < .02, respectively). The 2-year LRC rate for 8 patients who had received consolidative IFRT was 100% compared with 36% for the 11 patients who had not received consolidative IFRT (P < .01). Likewise, the 2-year PFS rate was better (88% vs. 27%; P ¼ .01), as was the 2-year OS rate (100% vs. 45%; P ¼ .02). The Kaplan-Meier plots for patients with ! 2 cm residual nodal disease after ASCT are depicted in Figure 2 .
Stem cell transplantation with or without consolidative RT was well tolerated, with acceptable toxicities. All patients developed grade 3 anemia. Other toxicities were limited to grade 1 (30 events) and grade 2 (21 events) and included diarrhea (23 events), nausea (15 events), pneumonia (4 events), pericarditis (1 event), cardiomyopathy (1 event), and arterial thrombosis (1 event) . No treatment-associated deaths, radiation pneumonitis, or secondary malignancies were observed in this patient group. No significant differences were found in the proportion of patients who had developed grade 1 or 2 toxicities between those who had and had not received consolidative IFRT (68% vs. 69%; P ¼ .92).
Discussion
In the present retrospective analysis, those patients who had received IFRT experienced a significant improvement in LRC among patients who had undergone ASCT for relapsed or refractory DLBCL. Only 8% of patients who received consolidative IFRT developed a relapse compared with 32% of those who had not received IFRT (P ¼ .04).
Several other retrospective studies have addressed the use of consolidative IFRT in the peritransplant setting (Table 4) . 3, 4, 6, [9] [10] [11] [12] [13] [14] These studies differed by the subtype of non-Hodgkin lymphoma ), and indications for consolidative RT. Consistent with our report, most studies found improved outcomes with consolidative IFRT. 4, 6, [9] [10] [11] [12] The results of our cohort productively add to these data, because our patients were homogenous in eligibility, uniformly treated using a single treatment protocol, and consistently monitored after ASCT.
When we restricted our analysis to include only the subgroup of patients with residual nodal disease ! 2 cm seen on day 28 after post-ASCT imaging, we found significant improvement associated with consolidative IFRT, not only in LRC, but also in PFS and OS. The number of patients in this subset was small, but the results suggest a possible subgroup of patients who are likely to derive the greatest benefit from consolidative IFRT. The improvement observed in this group of patients appears to be consistent with previous reports that relapse at pre-ASCT sites of disease remains the most common pattern of post-ASCT failure. Aggressive local control using consolidative IFRT, therefore, could have an effect on transplantation outcomes.
Because of the potential importance of local disease control at previous sites of involvement, we reanalyzed the status of the involved lymph nodes using both CT and PET data. We re-evaluated the size of the lymph nodes on the CT scans before ASCT and at day 28 for all 72 patients. In 19 of these patients, ! 1 residual lymph node measured ! 2 cm. The treatment protocol recommended consolidative RT for such patients; however, only 8 of the 19 patients received it. When we reviewed the post-ASCT day 100 PET/CT scans using the Deauville criteria for the 11 patients who had not received consolidative RT, 9 had a Deauville score of 4. Evaluation of the PET scans using Deauville criteria was not routinely performed during the study period. In all these cases, the radiologist interpreting the PET-CT scans had reported either stable disease or that the disease was responding to the current treatment. This reporting style might have swayed the medical oncologists away from referring patients for consolidative IFRT. Additionally, oncologists might have been concerned about the potential for added toxicity associated with post-transplant consolidative IFRT after TBI. Therefore, routine use of the Deauville criteria in PET scan reports of patients with lymphoma should be recommended for standardized communication of disease status, because this could have important implications for treatment decisions.
A concern regarding using consolidative IFRT in the peritransplant setting is the potential increase in morbidity. Depending on the treatment site, patients are at risk of developing radiation pneumonitis, cardiomyopathy, mucositis, and secondary myelodysplastic syndromes. 3, 5, 15, 16 We did not observe significant radiation-related toxicities among the patients in our study. Aside from the expected grade 3 anemia from transplant, most patients experienced only grade 1 or 2 toxicities, and no significant difference was found in the frequency of toxicities between patients who had and had not received consolidative IFRT. Many other studies have also reported similar findings.
11,12,14
Longer patient follow-up data would be needed to assess the late effects of RT, such as secondary malignancy; however, this seems to be of less concern in the DLBCL population than in the Hodgkin lymphoma population, who tend to be younger. In addition, concern exists that the timing of the consolidative RT could influence the occurrence of toxicity. In our series, all patients who received IFRT did so after ASCT and had completing IFRT a median of 110 days after transplantation. We observed no added toxicity. In contrast, Tsang et al 16 reported that 8 of 10 transplant-related deaths were associated with pretransplant IFRT directed at the mediastinum. Similarly, Friedberg et al 3 found an adverse effect of pretransplant IFRT on survival in patients undergoing transplantation, which was attributed to the occurrence of secondary myelodysplasia or pulmonary complications. Fewer than 50 days between IFRT and ASCT or a large radiation field size (including larger portions of the lungs) were also associated with worse morbidity and mortality. 3, 5, 16, 17 Avoiding these hazards, Hoppe et al 18 reported that IFRT before HDC in the setting of ASCT resulted in minimal treatment-related morbidity and mortality. Our results suggest that if IFRT is to be considered in the ASCT setting, it should be delivered after ASCT, with allowance for adequate recovery from the toxicity of the transplantation. Most patients in the present series had undergone a conditioning regimen that had included TBI. How much the modest dose of TBI contributes to tumor control is unknown; however, generally, 1320 cGy would be considered an inadequate radiation dose for lymphoma. Starting in 2014 at UMN, the ASCT preparative regimen was altered to replace TBI with BEAM chemotherapy for most patients, because the available data suggested it has equivalent efficacy to a TBI-containing regimen. 19 It remains to be seen how this change will affect the LRC rate; however, the change to BEAM has provided an opportunity to use consolidative RT in more patients, with the possibility of delivering higher doses to achieve optimal disease control. The appropriate radiation dose for peritransplant consolidative IFRT is not known; however, in the present series, the doses ranged from 3060 to 3600 cGy.
Conclusion
Patients with relapsed or refractory DLBCL are at high risk of relapse after ASCT. The most common site of failure in these patients was the site of disease before ASCT, reflecting poor LRC. We found that patients selected to receive consolidative RT directed at the involved sites experienced significantly improved LRC. Additionally, among the patients with nodal masses ! 2 cm on post-transplant imaging, those selected to receive IFRT had improved PFS and OS. Further studies, ideally in the form of randomized prospective trials, are necessary to definitively determine the role of RT in the peritransplant setting. However, our study results appear to suggest a benefit from consolidative RT in select patient populations.
Clinical Practice Points
High dose chemotherapy combined with autologous stem cell transplantation (HDT/ASCT) has become the standard salvage approach for relapsed or refractory DLBCL, but many patients continue to relapse especially in previous sites of disease. Several retrospective studies have investigated the efficacy of consolidative radiotherapy in conjunction with HDT/ASCT DLBCL, but consensus on which patients benefit has not yet been reached. Most studies have shown that consolidative radiotherapy (either before or after ASCT) decreases relapse with acceptable toxicity.
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